Nordic Life Science 1
T E X T b y M AL IN O T M ANI BUSINE S S D E A L
3D illustration of Clostridium difficile bacterium. It causes pseudomebraneous colitis and is associated with nosocomial antibiotic resistance. John Daicic, CEO, Atlas Antibodies A NTIB I O TI C R E S I S TA NC E tissue-like properties that enhance the quality of tissue-based assays. HistoCyte has established a significant presence in important markets. The company has a strong growth trajectory that is expected to accelerate as acceptance of cell line controls increases rapidly, according to Atlas Antibodies. “Our proteome-wide portfolio of antibody reagents, in synergy with HistoCyte’s novel cell line controls, will provide a powerful set of tools for researchers and clinicians working to understand and diagnose some of the most challenging health issues of our time,” says John Daicic, CEO, Atlas Antibodies. the use of antibiotics has led to a growing global problem in the form of antibiotic-resistant bacteria. For this reason, the Nordic Council invited members of other parliamentary bodies to a webinar, “Antibiotic resistance – a silent threat in a noisy pandemic era”, to further discuss what concrete actions and measures must be taken next to deal with the threat of AMR in the light of COVID-19. It has been decades since the pharmaceutical industry produced new types of antibiotics and the regulatory frameworks for the industry make it difficult for manufacturers to convince themselves and investors that it would be worthwhile. Bente Mathisen, Chair of the Nordic Council Committee for Welfare in the Nordic region, said he is willing to consider financial incentives to encourage the production of new antibiotics. At the webinar, COVID-19 was described as a wake-up call that shows how important it is that health agencies are geared up to meet needs in times of crisis, but also in the future. NORDIC LIFE SCIENCE 7